Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma.

Breinig M, Caldas-Lopes E, Goeppert B, Malz M, Rieker R, Bergmann F, Schirmacher P, Mayer M, Chiosis G, Kern MA.

Hepatology. 2009 Jul;50(1):102-12. doi: 10.1002/hep.22912.

PMID:
19441108
2.

Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice.

Lang SA, Moser C, Fichnter-Feigl S, Schachtschneider P, Hellerbrand C, Schmitz V, Schlitt HJ, Geissler EK, Stoeltzing O.

Hepatology. 2009 Feb;49(2):523-32. doi: 10.1002/hep.22685.

PMID:
19085954
3.

The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.

Leng AM, Liu T, Yang J, Cui JF, Li XH, Zhu YN, Xiong T, Zhang G, Chen Y.

Cell Biol Int. 2012 Oct 1;36(10):893-9. doi: 10.1042/CBI20110473.

PMID:
22694478
4.

Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.

Watanabe G, Behrns KE, Kim JS, Kim RD.

Cancer Chemother Pharmacol. 2009 Aug;64(3):433-43. doi: 10.1007/s00280-008-0888-2.

5.

Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.

Schwock J, Pham NA, Cao MP, Hedley DW.

Cancer Chemother Pharmacol. 2008 Apr;61(4):669-81.

PMID:
17579866
6.

The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.

Usmani SZ, Bona RD, Chiosis G, Li Z.

J Hematol Oncol. 2010 Oct 26;3:40. doi: 10.1186/1756-8722-3-40.

7.

17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.

Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.

Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2348-56. doi: 10.1167/iovs.07-1305.

PMID:
18281615
9.

Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.

Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK, Stoeltzing O.

Mol Cancer Ther. 2007 Mar;6(3):1123-32.

10.

SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.

Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, Norton L, Rosen N, Solit DB.

Clin Cancer Res. 2008 Jan 1;14(1):240-8. doi: 10.1158/1078-0432.CCR-07-1667.

11.

Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.

Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O.

Mol Cancer Ther. 2007 Nov;6(11):2868-78.

12.

Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.

Sanderson S, Valenti M, Gowan S, Patterson L, Ahmad Z, Workman P, Eccles SA.

Mol Cancer Ther. 2006 Mar;5(3):522-32.

14.

19-substituted benzoquinone ansamycin heat shock protein-90 inhibitors: biological activity and decreased off-target toxicity.

Chang CH, Drechsel DA, Kitson RR, Siegel D, You Q, Backos DS, Ju C, Moody CJ, Ross D.

Mol Pharmacol. 2014 Jun;85(6):849-57. doi: 10.1124/mol.113.090654.

15.

Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.

Srethapakdi M, Liu F, Tavorath R, Rosen N.

Cancer Res. 2000 Jul 15;60(14):3940-6.

16.

The Hsp90 inhibitor SNX-2112 induces apoptosis of human hepatocellular carcinoma cells: the role of ER stress.

Wang X, Wang S, Liu Y, Ding W, Zheng K, Xiang Y, Liu K, Wang D, Zeng Y, Xia M, Yang D, Wang Y.

Biochem Biophys Res Commun. 2014 Mar 28;446(1):160-6. doi: 10.1016/j.bbrc.2014.02.081.

PMID:
24582562
17.

Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.

Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2004 Dec 1;10(23):8077-84.

19.

17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces mitochondria-mediated apoptosis through downregulation of Mcl-1 in human hepatocellular carcinoma cells.

Zhao S, Li H, Jiang C, Ma T, Wu C, Huo Q, Liu H.

J Bioenerg Biomembr. 2015 Oct;47(5):373-81. doi: 10.1007/s10863-015-9620-1.

PMID:
26323360
20.

Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.

Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D.

Cancer Res. 2003 Dec 15;63(24):8984-95.

Items per page

Supplemental Content

Support Center